First Patient Dosed in ATL1102 Phase IIb DMD Trial
Released
Released
Announcement PDF
ASX Announcement
8 June 2023
First Patient Dosed in ATL1102 Phase IIb Duchenne Muscular Dystrophy (DMD) Trial
Key Highlights:
First patient with DMD received ATL1102 or Placebo, in Turkey, on 6 June 2023.
3 patients currently in screening phase of the trial.
Trial to recruit 45 male patients aged 10 to <18 years across at least 12 clinical sites in 4
countries.
Results from the initial 24-week treatment period anticipated mid-2024.
Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY] (ANP or Company) is pleased
to announce a significant milestone in the development of ATL1102 for Duchenne muscular dystrophy.
Recruitment has commenced in the multicentre double-blind, placebo-controlled Phase IIb trial of
ATL1102 in non-ambulant boys with DMD and the first participant has been randomised and dosed
with ATL1102 or Placebo in Turkey. This first patient was enrolled by Professor Haluk Topaloglu MD,
Yeditepe University Kosuyolo Hospital Istanbul, Turkey.
“This is a major milestone for Antisense Therapeutics and the DMD community”, said Dr Charmaine
Gittleson, Antisense Board Chair. “I am excited that ATL1102 has again entered a clinical trial and we
genuinely hope the study participants and future patients with DMD will benefit from this treatment.”
The Phase IIb trial, led by Coordinating Principal Investigator Professor Thomas Voit MD, University
College London United Kingdom (UK), will evaluate the effect of ATL1102 on upper limb muscle
function in non-ambulant participants with DMD, as assessed by (i) difference in the Performance of
Upper Limb Module for DMD 2.0 (PUL 2.0) score against placebo at 6 months; (ii) stabilisation or
improvement of clinical effect after 12 months of treatment; and (iii) the clinical impact of delayed
treatment between the placebo and active treatment groups.
The trial is a two-part design to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics
of ATL1102. Participants will be enrolled and randomised to receive either ATL1102 (25mg dose),
ATL1102 (50mg dose) or matched placebo in a 1:1:1 ratio given as a weekly subcutaneous injection
for a 24-week randomized, double-blind, placebo-controlled treatment period (Part A). Efficacy and
safety data will be assessed at the end of Part A. Participants will then continue to the Open Label
Extension treatment period (Part B) and continue to receive ATL1102 (25mg or 50mg dose) for a
further 24 weeks. Participants on placebo in Part A will cross over to receive ATL1102 in Part B. A four
month follow up period occurs after Part B. Further trial details will shortly be available for public view
on clinicaltrials.gov.
Professor Voit noted “I am very pleased that the ATL1102 Phase IIb clinical trial has commenced
patient enrolment. There is high need for new therapeutic approaches for the treatment of DMD and
this trial is an important step towards finding effective treatment options for DMD patients and
providing hope for their families.”
LEVEL 1, 14 WALLACE AVENUE, TOORAK VIC 3142 AUSTRALIA TEL . +61 3 9827 8999 FAX +61 3 9859 7701 WEB WWW.ANTISENSE.COM.AU
ANTISENSE THERAPEUTICS LIMITED - ABN 41 095 060 745
Page 1 of 2
The trial will be conducted across at least 12 clinical sites located in Australia, Bulgaria, United Kingdom
and Turkey. Presently Turkey and Bulgaria have regulatory approvals with Turkish sites actively
screening potential participants. Site activation in Bulgaria is imminent. In Australia, ethics approval
has been granted and the Clinical Trial Notification submitted to the Therapeutic Goods Administration
and we are currently awaiting final institutional (hospital) approval. Approval from the MHRA in the UK
is anticipated within the coming weeks. Once all countries and sites are open the Company looks
forward to recruitment accelerating accordingly.
As we progress through the trial, we look forward to sharing investor updates on significant
developments as they become available.
For more information please contact:
Antisense Therapeutics
Charmaine Gittleson
Executive Chair
+61 (0)3 9827 8999
www.antisense.com.au
Investment Enquiries
Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
1300 932 037
US/European IR & Media
Laine Yonker/Joe Green
Edison Investor Relations
lyonker@edisongroup.com
+1 646-653-7035
This announcement has been authorised for release by the Board.
About Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] is a publicly listed
biotechnology company developing and commercializing antisense pharmaceuticals for rare diseases with
significant unmet medical need. The company’s lead program is ATL1102, an antisense inhibitor of the CD49d
receptor, which is currently the subject of an ongoing international Phase IIb trial for Duchenne Muscular
Dystrophy. The drug previously reported highly promising results from an exploratory Phase II trial.
LEVEL 1, 14 WALLACE AVENUE, TOORAK VIC 3142 AUSTRALIA TEL . +61 3 9827 8999 FAX +61 3 9859 7701 WEB WWW.ANTISENSE.COM.AU
ANTISENSE THERAPEUTICS LIMITED - ABN 41 095 060 745
Page 2 of 2
Share your feedback
Discover